Vericel Corporation (VCEL)

43.74 -0.12 (-0.27%) At close: 04:00PM EDT

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States
617 588 5555
https://vcel.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 314

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dominick C. Colangelo Esq.	CEO, President & Director	1.54M	1.51M	1964
Mr. Joseph Anthony Mara Jr.	CFO & Treasurer	750.61k	N/A	1976
Mr. Sean C. Flynn	Chief Legal Officer	657.01k	N/A	1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.	Chief Medical Officer	672.16k	127.25k	1962
Mr. Jonathan D. Siegal	Principal Accounting Officer, VP & Corporate Controller	N/A	N/A	N/A
Mr. Eric Burns	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. Patrick J. Fowler	Senior Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Mr. Patrick Helfrich	Vice President of Marketing & Commercial Strategy	N/A	N/A	N/A
Mr. Mike Gilligan	Senior Vice President of Sales	N/A	N/A	N/A
Ms. Heidi Hassen	Senior Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Vericel Corporation’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.